Vertex Pharmaceuticals Inc VRTX
News
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
Vertex to Announce Second Quarter 2024 Financial Results on August 1
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
Vertex Pharmaceuticals on Track for Record High Close — Data Talk
Vertex to Participate in Upcoming June Investor Conferences
Vertex Pharmaceuticals on Track for Record High Close — Data Talk
Vertex Pharmaceuticals on Track for Record High Close — Data Talk
Jennifer Schneider Elected to Vertex Board of Directors
Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
Vertex Reports First Quarter 2024 Financial Results
Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics
VERTEX AND TREEFROG THERAPEUTICS ANNOUNCE LICENSING AGREEMENT AND COLLABORATION TO OPTIMIZE PRODUCTION OF VERTEX'S CELL THERAPIES FOR TYPE 1 DIABETES
Vertex's stock climbs as non-opioid pain treatment advances
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vera Therapeutics Shares Rise 9.9% After Alpine Acquisition
Alpine Immune Sciences Shares Rally After Vertex Agrees to Acquire Co.
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion — Update
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion